Valproate-associated coagulopathies are frequent and variable in children

Epilepsia

Volumn 47, Issue 7, 2006, Pages 1136-1143

  Gerstner, Thorsten ^a   Teich, Martin ^a   Bell, Nellie ^a   Longin, Elke ^a   Dempfle, Carl Erik ^a   Brand, Joachim ^b   König, Stephan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Johanniter Children Hospital   (Germany)

Author keywords

Coagulopathy; Factor XIII; Platelets; Valproate; Von Willebrand

Indexed keywords

BLOOD CLOTTING FACTOR 13; FELBAMATE; FIBRINOGEN; VALPROIC ACID; VIGABATRIN; VON WILLEBRAND FACTOR;

ABSENCE; ARTICLE; BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 13 DEFICIENCY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEBRILE CONVULSION; FEMALE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HUMAN; HYPOFIBRINOGENEMIA; LENNOX GASTAUT SYNDROME; MALE; MYOCLONUS SEIZURE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; STATISTICAL SIGNIFICANCE; SURGICAL TECHNIQUE; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; VITAMIN K DEFICIENCY; VON WILLEBRAND DISEASE;

AGE FACTORS; ANTICONVULSANTS; BLOOD COAGULATION TESTS; CHILD; COAGULATION PROTEIN DISORDERS; EPILEPSY; FEMALE; HEMOPHILIA A; HUMANS; INCIDENCE; INFANT; MALE; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; THROMBELASTOGRAPHY; THROMBOCYTOPENIA; VALPROIC ACID; VON WILLEBRAND DISEASE;

EID: 33746126842     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2006.00587.x     Document Type: Article

References (82)

1. Ware S, Millward-Sadler GH. Acute liver failure associated with sodium valproate. Lancet 1980;2:1110-32.
2. Sleiman C, Raffy O, Roué C, Mal H. Fatal pulmonary hemorrhage during high-dose valproate monotherapy. Chest 2000;117:613.
3. Rajantie J, Kajosaari M, Ylitalo V. Fatal pancytopenia during high-dose valproate monotherapy (letter). Eur J Pediatr 1992;151:619.
4. Kaya IS, Dilmen U, Toppare M, et al. Valproic-acid-induced pancytopenia and Coombs test positivity. Lancet 1991;337:1227-8.
5. Ward MW, Barbaro NW, Laxer KD, et al. Preoperative valproate administration does not increase blood loss during temporal lobectomy. Epilepsia 1996;37:98-101.
6. Anderson G, Lin YX, Berge C, et al. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg 1997;87:252-6.
7. Koch-Weser J, Browne TR. Drug therapy: valproic acid. N Engl J Med 1980;302:661-6.
8. Schmidt D. Adverse effects of valproate. Epilepsia 1984;25:44-9.
9. Allen GC, Armfield DR, Bontempo FA, et al. Adenotonsillectomy in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg 1999;125:547-51.
10. Chambers HG, Weinstein CH, Mubarak SJ, et al. The effect of valproic acid on blood loss in patients with cerebral palsy. J Pediatr Orthop 1999;19:792-5.
11. Winter SL, Kriel NL, Novacheck TF, et al. Perioperative blood loss: the effect of valproate. Pediatr Neurol 1996;15:19-22.
12. Loiseau P. Sodium valproate, platelet dysfunction and bleeding. Epilepsia 1981;22:141-6.
13. Gidal B, Spencer N, Maly M, et al. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology 1994;44:1418-22.
14. Eastham RD, Jancar J. Letter: Sodium valproate and platelet counts. Br Med J 1980;280:186.
15. von Czettritz G, Weinmann HM. Gerinnungsstörung unter Valproinsäure. In: Krämer G, Laub M, eds. Valproinsäure. Heidelberg: Springer-Verlag, 1992:210-6.
16. Zeller JA, Schlesinger S, Runge U, et al. Influence of valproate monotherapy on platelet activation and hematologic values. Epilepsia 1999;40:186-9.
17. Hauser E, Seidl R, Freilinger M, et al. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev 1996;18:105-9.
18. May RB, Sunder TR. Hematologic manifestations of long-term valproate therapy. Epilepsia 1993;34:1098-101.
19. Barr RD, Copeland SA, Stockwell ML, et al. Valproic acid and immune thrombocytopenia. Arch Dis Child 1982;57:681-4.
20. Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982;23:693-720.
21. Neophytides AN, Nutt JG, Lodish JR. Thrombocytopenia associated with sodium valproate treatment. Ann Neurol 1979;5:389-90.
22. Krause KH. Thrombozytenwerte bei Erwachsenen unter Behandlung mit DPA (Ergenyl). Med Welt 1977;28:1098-9.
23. Tanindi Ş, Akin R, Köseoǧlu, et al. The platelet aggregation in children with epilepsy receiving valproic acid. Thromb Res 1996;81:471-6.
24. Delgado MR, Riela AR, Mills J, et al. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol 1994;9:311-4.
25. Watts RG, Emanuel PD, Zuckerman KS, et al. Valproic acid-induced cytopenias: evidence for a dose related suppression of hematopoiesis. J Pediatr 1990;117:495-9.
26. Ganick DJ, Sunder T, Finley JL. Severe hematologic toxicity of valproic acid: a report of four patients. Am J Pediatr Hematol Oncol 1990;12:80-5.
27. Sherbany AA, Rothman SJ, Jayabose S. Delayed-onset dose-related valproate-induced thrombocytopenia. Neurology 1990;40:137.
28. Cheng RD, Kohrman MH, Kerr SL, et al. Thrombocytopenia associated with valproic acid that requires platelet transfusion. Ann Neurol 1989;26:457-8.
29. Smith FR, Boots M. Sodium valproate and bone marrow suppression. Ann Neurol 1980;8:197-9.
30. Sutor AH, Jesdinsky-Buscher C. (Alteration of hemostasis during anticonvulsive Therapy with dipropyl-acetate (DPA), further observations). Fortschr Med 1976;94:411-4.
31. Kishi T, Fujita N, Kawaguchi H, et al. Bone marrow suppression induced by high dose valproic acid. Arch Dis Child 1994;71:153-5.
32. Stahl MMS, Neiderud J, Vinge E. Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid. J Pediatr 1997;130:1001-3.
33. Bruni J, Wilder BJ. Valproic acid: review of a new antiepileptic drug. Arch Neurol 1979;53:73-80.
34. Sandler RM, Emberson C, Roberts GE, et al. IgM platelet autoantibody due to sodium valproate. Br Med J 1978;2:1683-4.
35. Tetzlaff JE. Intraoperative defect in haemostasis in a child receiving valproic acid. Can J Anaesth 1991;38:222-4.
36. Keenan JP, Wharton J, Sheperd AJN, et al. Defective platelet lipid peroxidation in myeloproliferative disorders: a possible defect of prostaglandin synthesis. J Haematol 1977;35:275.
37. von Hoss H, Schulte-Berbühl R, Göbel U. Side effects of sodium valproate (sodium di-N-propylacetate) on malonyldialdehyde-production and other platelet function tests. Min Pediatr 1978;30:1397-404.
38. Kis B, Szupera Z, Mezei Z, et al. Valproate treatment and platelet function: the role of arachidonate metabolites. Epilepsia 1999;40:307-10.
39. Ozkara C, Dreifuss FE, Apperson Hansen C. Changes in red blood cells with valproate therapy. Acta Neurol Scand 1993;88:210-2.
40. König SA, Siemes H, Blaker F, et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 1994;35:1005-15.
41. Kreuz W, Mentzer D, Becker S, et al. Haemate P in children with von Willebrand's disease. Haemostasis 1994;24:304-10.
42. Corrigan JJ. Hemorrhagic and thrombotic diseases. In: Nelson WE, Behrman RE, Kliegman RM, et al., eds. Textbook of pediatrics, 15th ed. London: WB Saunders, 1996:1422-38.
43. Gil-Fernandez JJ. Letter to editor. Epilepsia 1997;38:1257-8.
44. Koscielny J, Blaicher AM, Felfernig D, et al. Consensus use of desmopressin and antifibrinolytics in three university clinics. Anaesthesia 1998;53:60-2.
45. Lethagen S. Desmopressin: a hemostatic drug: state-of-the-art review. Eur J Anaesthesiol 1997;14:1-9.
46. Lethagen S, Frick K, Sterner G. Antidiuretic effect of desmopressin given in hemostatic dosages to healthy volunteers. Am J Hematol 1998;57:153-9.
47. 2 receptor subtype in the central nervous system. Brain Res 1997;759:18-23.
48. Bernstein SA, Williford SL. Intranasal desmopressin-associated hyponatremia: a case report and literature review. J Fam Pract 1997;44:203-8.
49. Apakama DC, Bleetman A. Hyponatraemic convulsion secondary to desmopressin treatment for primary enuresis. J Accid Emerg Med 1999;16:229-30.
50. Schwab M, Wenzel D, Ruder H. Hyponatraemia and cerebral convulsion due to short term DDAVP therapy for control of enuresis nocturna. Eur J Pediatr 1996;155:46-8.
51. Frölich J, Wiater A. (Hyponatremia with cerebral convulsions: complications of a treatment of enuresis nocturna with desmopressin). Monatsschr Kinderheilkd 2000;148:768-70.
52. Heene DL, Matthias FR. Koagulopathien. In: Begemann H, Rastetter J, eds. Klinische Hämatologie. 4th ed. Stuttgart: Georg Thieme Verlag, 1993:828-69.
53. Anai T, Hirota Y, Oga M, et al. PIVKA II (protein induced by vitamin K absence-II) status in newborns exposed to anticonvulsant drugs in utero [Abstract]. Nippon Sanka Fujinka Gakkai Zasshi 1991;43:347-50.
54. Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Increased incidence of neonatal vitamin K deficiency resulting from maternal anticonvulsant therapy. Am J Obstet Gynecol 1993;168:923-8.
55. Thomas L. Hämostase bei Kindern, Schwangeren und bestimmten Erkrankungen. In: Thomas L, ed. Labor und Diagnose. Frankfurt/Main: TH-Books Verlagsgesellschaft mbH, 1998:600-6.
56. Fickenscher K. Gerinnungsfaktoren-Einzelanalysen. In: Thomas L, ed. Labor und Diagnose. Frankfurt/Main: TH-Books Verlagsgesellschaft mbH, 1998:621-4.
57. Rothschild BM. Hematologic perturbations associated with salicylate. Clin Pharmacol Ther 1979;26:145-52.
58. Zaugg H. Sind salicylartige Analgetika Vitamin K-Antagonisten? Eine Deutung der spontanen subnormalen Quickwerte. Schweiz Med Wschr 1978;108:1277-8.
59. Mountain KR, Hirsch J, Gallus AS. Neonatal coagulation defect due to anticonvulsant drug treatment in pregnancy. Lancet 1970;1:265-8.
60. Yerby MS. Risks of pregnancy in women with epilepsy. Epilepsia 1992;33:23-7.
61. Rochel M, Ehrenthal W. Haematological side effects of valproic acid. In: Oxley J, ed. Chronic toxicity of antiepileptic drugs. New York: Raven Press, 1983:101-3.
62. Cordes I, Buchmann S, Scheffner D. (Vitamin K deficiency under treatment with erythromycin. Clinical course of a boy treated with valproic acid). Monatsschr Kinderheilkd 1990;138:85-7.
63. Tam DA, Myer EC. Vitamin K-dependant coagulopathy in a child receiving anticonvulsant therapy. J Child Neurol 1996;11:244-6.
64. Frick PG, Riedler G, Brogli H. Response and minimal daily requirement for vitamin K in man. J Appl Physiol 1967;23:387.
65. Bayer W, Schmidt K. Vitamin K. In: Bayer W, Schmidt K, eds. Vitamine in Prävention und Therapie. Stuttgart: Hippokrates-Verlag, 1991:89-102.
66. Bechtold H, Andrassy K. Vitamin K und medikamenteninduzierte Hypoprothrombinämie. Hämostaseologie 1988;8:8-17.
67. 1 elimination in man. Eur J Clin Pharmacol 1987;33:93-5.
68. 1 (phylloquinone) in man. Biochem Med 1980;24:250-67.
69. Wagner C, Dato F. Fibrinogen. In: Thomas L, ed. Labor und Diagnose. Frankfurt/Main: TH-Books Verlagsgesellschaft mbH, 1998:624-7.
70. Echinaz-Laguna A, Thiriaux A, Ruolt-Olivesi I, et al. Lupus anticoagulant induced by the combination of valproate and lamotrigine. Epilepsia 1999;40:1661-3.
71. Gadner H, Bensel I, Grimm B, et al. Beeinflussung der Hämostase durch Dipropylessigsäure. Monatsschr Kinderheilkd 1976;124:448-9.
72. Majer RV, Green PJ. Neonatal afibrinogenaemia due to sodium valproate. Lancet 1987;2:740-1.
73. Dale BM, Purdie GH, Rischbieth RH. Fibrinogen depletion with sodium valproate. Lancet 1978;17:1316-7.
74. Monnet P, David M, Philippe N, et al. Altérations de l'hémostase lors des traitements au dipropylacetate de sodium. Pédiatrie 1979;34:603-20.
75. Bavoux F, Fournier-Perhilou AI, Wood C, et al. Neonatal fibrinogen depletion caused by sodium valproate. Ann Pharmacother 1994;28:1307.
76. Tokuda K, Kodani N, Ogino T. Three cases of hypofibrinogenemia induced by chemotherapy with a combination of synthetic ACTH and valproic acid [Abstract]. No To Hattatsu 1994;26:50-6.
77. Ojemann LM, Wilensky AJ, Temkin NR, et al. Fibrinogen and valproic acid. Epilepsia 1981;22:242-3.
78. Fickenscher K. Faktor XIII. In: Thomas L, ed. Labor und Diagnose. Frankfurt/Main: TH-Books Verlagsgesellschaft mbH, 1998:627-8.
79. Nicholson JF, Pesce MA. Laboratory medicine and reference tables. In: Nelson WE, Behrman RE, Kliegman RM, et al., eds. Textbook of pediatrics. 15th ed. London: WB Saunders, 1996:2031-84.
80. Thies HA, Richter H. Erworbener Faktor XIII-Mangel und klinische Chirurgie. Med Welt 1981;32:250-5.
81. Tilsner V. Blutungskomplikationen in der perioperativen Phase. In: Mammen EF, ed. Intensivmedizin aktuell. Marburg: Medizinische Verlagsgesellschaft, 1987:32-45.
82. Pohlmann-Eden B, Peters CN, Wennberg R, et al. Valproate induces reversible factor XIII deficiency with risk of perioperative bleeding. Acta Neurol Scand 2003;108:142-5.